The Common Fund’s Molecular Libraries and Imaging program offers biomedical researchers access to the large-scale screening capacity necessary to identify small molecules that can be optimized as chemical probes to study the functions of genes, cells, and biochemical pathways in health and disease. They may also be used by researchers in the public and private sectors to validate new drug targets, which could then move into the drug-development pipeline. Components of the Molecular Libraries program include:
- The Molecular Libraries Probe Production Centers Network (MLPCN)
- Technology Development
Related Funding Initiatives
Please see new funding opportunities related to, but separate from, this Common Fund program!
- PAR-13-134 High Throughput Screening (HTS) to Discover Chemical Probes (X01)
- PAR-13-135 High Throughput Screening (HTS) to Discover Chemical Probes (R03)
- PAR-12-058 Solicitation of Assays for High Throughput Screening (HTS) to Discover Chemical Probes (R01)
- PAR-12-059 Solicitation of Assays for High Throughput Screening (HTS) to Discover Chemical Probes (R21)
- PAR-12-060 Solicitation of Validated Hits for the Discovery of in vivo Chemical Probes (R01)
- PAR-11-319 Scalable Assays for Unbiased In Vitro Analysis of Neurobiological Function (R21/R33)
From Bench to Bedside: Therapeutic Candidate Targeting S1P1 Advances in Clinical Trials for Multiple Sclerosis
Receptos, Inc. announced in December, 2013 that they have completed an analysis of the Phase 2 portion of its Phase 2/3 trial of RPC1063 in relapsing multiple sclerosis (RMS). A compound initially discovered by the NIH Molecular Libraries Probe Production Center at The Scripps Research Institute, which is part of the NIH Common Fund Molecular Libraries Program, was used as a precursor in the development of RCPT1063 by Receptos Inc.
New BioAssay Research Database launches
BARD is powerful new bioassay database from the NIH Molecular Libraries Program. This newly launched database allows researchers to develop and test hypotheses on the influence of different chemical probes on biological functions. BARD’s constantly growing database currently includes more than 35 million compounds, 4 thousand assays, and over 300 projects.